Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: a systematic review to inform risk assessment in the COVID-19 era - Campbell, C; Andersson, M I; Ansari, M A (Front Med (Lausanne), 2021)